$PFE Company News You'd have to be a dope to buy

New Post Public Reply Private Reply Replies (0) Message Board

Feb 20, 2014 at 10:42 AM

$PFE Company News

You'd have to be a dope to buy marijuana stocks 1:36 p.m. Feb. 13, 2014 - blogs.marketwatch.com
Australia regulator takes action against Pfizer 11:03 p.m. Feb. 12, 2014 - MarketWatch.com
Pfizer, GE, Boeing lead early Dow advancers 9:34 a.m. Feb. 11, 2014 - William L. Watts
Judge likely to throw the book at Martoma, experts say 4:00 p.m. Feb. 6, 2014 - blogs.marketwatch.com
Feds, pharma rivals team up on Alzheimer's 2:32 p.m. Feb. 6, 2014 - blogs.marketwatch.com
The big Merck news centers on cancer-drug collaborations with other giants 11:02 a.m. Feb. 5, 2014 - blogs.marketwatch.com
Merck 4Q profit falls on weaker sales 8:21 a.m. Feb. 5, 2014 - MarketWatch.com
Stock market live blog: Indexes break 2-day losing streak; Kors, Yum climb 3:43 p.m. Feb. 4, 2014 - blogs.marketwatch.com
Pfizer leads Dow after an upgrade on promising cancer-drug tests 11:07 a.m. Feb. 4, 2014 - blogs.marketwatch.com
Pfizer leads Dow with 3% gain following upgrade 10:11 a.m. Feb. 4, 2014 - Russ Britt
Pfizer leads Dow with 3.3% gain following upgrade 10:03 a.m. Feb. 4, 2014 - Russ Britt
Pfizer advances 4.2% at the open, leads Dow 9:33 a.m. Feb. 4, 2014 - Victor Reklaitis
U.S. stocks see worst selloff in several months 4:41 p.m. Feb. 3, 2014 - Anora Mahmudova
Biggest drops since June for Dow industrials, S&P 500: stock market live blog recap 4:26 p.m. Feb. 3, 2014 - blogs.marketwatch.com
Pfizer, Randgold gain in slumping stock market 3:52 p.m. Feb. 3, 2014 - Saumya Vaishampayan
Pfizer shares get a boost on positive results for breast-cancer treatment 10:37 a.m. Feb. 3, 2014 - blogs.marketwatch.com
Pfizer breast-cancer study meets endpoint 8:37 a.m. Feb. 3, 2014 - MarketWatch.com
The inscrutable gold timers 10:26 a.m. Jan. 30, 2014 - Mark Hulbert
Updates, advisories and surprises 5:31 p.m. Jan. 28, 2014 - MarketWatch
U.S. stocks rise; Dow breaks 5-day skid 5:02 p.m. Jan. 28, 2014 - Anora Mahmudova

Pfizer Inc (PFE): Today's Featured Drugs Laggard 5:01 p.m. Feb. 19, 2014 - TheStreet.com
Wall Street Winners: Were Analyst 2014 Picks Worth Their Salt? 8:53 a.m. Feb. 18, 2014 - Seeking Alpha
If Adam Smith Were Alive, He'd Be A Dividend Investor 6:51 a.m. Feb. 15, 2014 - Seeking Alpha
If Adam Smith Were Alive, He Would Be A Dividend Investor 6:51 a.m. Feb. 15, 2014 - Seeking Alpha
Dow Today: Pfizer (PFE) Leads The Day Higher, AT&T (T) Lags 10:00 a.m. Feb. 14, 2014 - TheStreet.com
AbbVie Deserves More Respect 6:30 a.m. Feb. 14, 2014 - TheStreet.com
Pfizer Needs a Healthy Dose of Investor Love 6:00 a.m. Feb. 14, 2014 - TheStreet.com
Pfizer's Finally a Buy 1:13 p.m. Feb. 13, 2014 - Barrons.com
10 Reasons To Buy Durect Right Now 10:45 a.m. Feb. 13, 2014 - Seeking Alpha
Australian regulator sues Pfizer over Lipitor sales tactics 9:58 a.m. Feb. 13, 2014 - Seeking Alpha
Pfizer Australia Faces Antitrust Probe 12:05 a.m. Feb. 13, 2014 - WSJ.com
Update on Bayer's Aleve - Analyst Blog 4:45 p.m. Feb. 12, 2014 - Zacks.com
Stock Market News for February 12, 2014 - Market News 10:06 a.m. Feb. 12, 2014 - Zacks.com
FDA News: Aleve Is Not Safer Than Advil, Ibuprofen & Celebrex 5:50 a.m. Feb. 12, 2014 - InvestorPlace.com
FDA Panel Rejects Changing Painkiller Labels 5:32 p.m. Feb. 11, 2014 - WSJ.com
Marginal Earnings Beat at Zoetis in Q4, Guidance Weak - Analyst Blog 10:57 a.m. Feb. 11, 2014 - Zacks.com
Zoetis Q4 Beats Estimates, But Guidance Hammers Stock 10:32 a.m. Feb. 11, 2014 - Investors Business Daily
Stock Market News for February 11, 2014 - Market News 10:06 a.m. Feb. 11, 2014 - Zacks.com
Pfizer Inc Stock Buy Recommendation Reiterated (PFE) 9:00 a.m. Feb. 11, 2014 - TheStreet.com
Zoetis Swings to Fourth-Quarter Profit 7:58 a.m. Feb. 11, 2014 - WSJ.com

Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference 10:00 a.m. Feb. 18, 2014 - BusinessWire - BZX
Galectin Therapeutics Leaps Ahead with SBH Sciences Partnership 11:02 a.m. Feb. 13, 2014 - ACCESSWIRE
Northeast Shows Nearly $7 Billion in Reasons to Love the Life Science Industry's Capital Investments, an Industrial Info News Alert 6:15 a.m. Feb. 13, 2014 - Marketwire
Pfizer Statement on Today’s Joint Meeting of FDA Advisory Committees 2:03 p.m. Feb. 11, 2014 - BusinessWire - BZX
Pfizer And Merck To Collaborate On Innovative Anti-Cancer Combination Studies 6:45 a.m. Feb. 5, 2014 - BusinessWire - BZX
Pain Therapeutics Reports 2013 Financial Results and Provides Guidance for 2014 10:48 p.m. Feb. 4, 2014 - GlobeNewswire
LiveWorld and Pfizer to Present a Series of Panels on Social Media Within Regulated Industries at Social Media Week 10:00 a.m. Feb. 4, 2014 - BusinessWire - BZX
Biotech News for Advancing Pharma Stocks: Company's Test Results Surpass Expectations For $3.5 Billion ADHD Market 9:05 a.m. Feb. 4, 2014 - PR Newswire - PRF
TrendingWallStreet.com Initiates Trend Analysis on GFOX, CMCSA, SKTO, and PFE 12:22 a.m. Feb. 4, 2014 - ACCESSWIRE
Pfizer Announces Positive Top-Line Results From PALOMA-1 Evaluating Palbociclib Plus Letrozole in Women with Advanced Breast Cancer 7:00 a.m. Feb. 3, 2014 - BusinessWire - BZX
Critical Alerts For Twitter, Alexion Pharmaceuticals, Pfizer, Ctrip, and AngloGold Ashanti Released By InvestorsObserver 9:31 a.m. Jan. 31, 2014 - PR Newswire - PRF
Pfizer Reports Fourth-Quarter and Full-Year 2013 Results;Provides 2014 Financial Guidance 7:01 a.m. Jan. 28, 2014 - BusinessWire - BZX
Pfizer Announces Top-Line Results From Two Phase 3 Trials Of Dacomitinib In Patients With Refractory Advanced Non-Small Cell Lung Cancer 7:00 a.m. Jan. 27, 2014 - BusinessWire - BZX
Pfizer Reports Top-Line Results From ALO-02 Phase 3 Study 8:00 a.m. Jan. 23, 2014 - BusinessWire - BZX
Pharmerging Markets 2012-2016 11:12 a.m. Jan. 22, 2014 - PR Newswire - PRF
New Survey Reveals What Match.Com Members Think About Smoking Cigarettes And Dating 10:00 a.m. Jan. 22, 2014 - BusinessWire - BZX
Lpath Granted Key U.S. Patent Related to Ocular Drug Program, iSONEP 7:30 a.m. Jan. 22, 2014 - PR Newswire - PRF
CHANTIX®/CHAMPIX® (varenicline) Demonstrates Smoking-Cessation Efficacy In Smokers Unwilling or Unable To Quit Abruptly 8:00 a.m. Jan. 21, 2014 - BusinessWire - BZX
ViiV Healthcare's new HIV medicine Tivicay™ (dolutegravir) is approved in Europe 6:52 a.m. Jan. 21, 2014 - PR Newswire - PRF
Statement from Pfizer Chief Medical Officer on the 50th Anniversary of the First Surgeon General's Report on Smoking and Health 10:15 a.m. Jan. 17, 2014 - BusinessWire - BZX

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

MRI Surveillance Gains Ground in Lung Cancer Care

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

GORGIE Unleashes Berry Burst: Target's New Drink Star

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

First-Time Homeowners: Unseen Pitfalls of Insurance

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

PwC US and India Unite for Global Consultancy Powerhouse

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Tam-Peli Steps Up in SCLC Battle: Trial Insights

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

UWM Faces Class Action Deadline: Key Insights for Investors

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Trial Disappointment: No Significant Gains in NSCLC

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Ris-Rez May Set New Standard in Relapsed SCLC

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...